Peer-reviewed veterinary case report
Outcome and side effects of intense chemo for dog lymphoma in 130
By Sorenmo, Karin et al.·Published in Veterinary and comparative oncology·2010·Department of Clinical Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
- Species:
- dog
Plain-English summary
A group of 130 dogs with lymphoma (a type of cancer) underwent a special chemotherapy treatment designed to be more intense but without the need for maintenance doses. Most of these dogs had advanced disease, and while the treatment was effective, many experienced side effects that required dose adjustments or treatment delays. Interestingly, those dogs that had their doses reduced or treatment postponed ended up having longer times before their cancer progressed and better survival rates. This suggests that while a more intense treatment can be beneficial, it should be tailored to each dog's tolerance to minimize side effects.
People also search for: dog lymphoma treatment options · chemotherapy side effects in dogs · how long can a dog live with lymphoma
Abstract
A dose-intensified/dose-dense chemotherapy protocol for canine lymphoma was designed and implemented at the Veterinary Hospital of the University of Pennsylvania. In this study, we describe the clinical characteristics, prognostic factors, efficacy and toxicity in 130 dogs treated with this protocol. The majority of the dogs had advanced stage disease (63.1% stage V) and sub-stage b (58.5%). The median time to progression (TTP) and lymphoma-specific survival were 219 and 323 days, respectively. These results are similar to previous less dose-intense protocols. Sub-stage was a significant negative prognostic factor for survival. The incidence of toxicity was high; 53.9 and 45% of the dogs needed dose reductions and treatment delays, respectively. Dogs that required dose reductions and treatment delays had significantly longer TTP and lymphoma-specific survival times. These results suggest that dose density is important, but likely relative, and needs to be adjusted according to the individual patient's toxicity for optimal outcome.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20691027/